Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with ...

A deep molecular analysis of failing human hearts suggests diabetes may directly alter cardiac metabolism, but experts differ ...

By Padmanabhan Ananthan Feb 18 (Reuters) - Cencora will sell its subsidiary MWI Animal Health to privately held Covetrus in a deal valuing the unit at $3.5 billion, the companies said on Wednesday, as ...

Zealand Pharma achieved notable organizational growth in 2025, with a 41% increase in the number of employees compared to 2024. Despite this rapid expansion, the company improved its high employee ...

Highlights: Heart health and heart disease risk go beyond the heart.Diabetes and kidney disease are major risk factors for ...

SHARJAH, 18th February, 2026 (WAM) -- The University of Sharjah (UoS) has convened a meeting with strategic partners for its Office of Women in Research to strengthen collaboration and support for ...

The global autogenous vaccines market is growing steadily, valued at around US$ 312.4 million in 2026 and projected to reach US$ 451.5 million by 2033, ...

Zealand reported revenue of DKK 9.22 billion for 2025, compared to just DKK 63 million in 2024, primarily driven by the Roche collaboration. Net operating expenses excluding other operating items were ...

The drugmaker terminated the first-in-human Phase I/II trial after a year, determining that the clinical data did not support further investigation.

In addition to the EUA, NexGard chewable tablets are FDA-approved for flea and tick-related indications in dogs and puppies. NexGard COMBO topical solution is FDA-approved for flea, tick, and ...

Company announcement - No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, ...